DHVI is pleased to announce the approval of a Phase 1 clinical trial of one of our most promising antibody treatments for COVID-19. This will be a temporary treatment until a vaccine is developed. Additionally, we are developing a pan-coronavirus vaccine that will combat future iterations of COVID-19 & similar viruses, and also researching if saliva can be used as an accurate indicator of COVID-19 infection.